ALLR

Allarity Therapeutics Inc

ALLR, USA

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

https://www.allarity.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALLR
stock
ALLR

Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Declines By 17.1% Defense World

Read more →
ALLR
stock
ALLR

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Cardio Diagnostics (NASDAQ:CDIO) Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$9.25

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.21

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

1.40

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-23.36 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-13.49 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Low

0.73

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 2.74% of the total shares of Allarity Therapeutics Inc

1.

Vanguard Institutional Extnd Mkt Idx Tr

(0.6142%)

since

2025/07/31

2.

XTX Topco Ltd

(0.3485%)

since

2025/06/30

3.

Geode Capital Management, LLC

(0.3465%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.3321%)

since

2025/07/31

5.

UBS Group AG

(0.3282%)

since

2025/06/30

6.

Jane Street Group LLC

(0.1803%)

since

2025/06/30

7.

Fidelity Total Market Index

(0.1525%)

since

2025/07/31

8.

Fidelity Series Total Market Index

(0.1477%)

since

2025/07/31

9.

Spartan Extended Market Index Pool F

(0.1064%)

since

2025/07/31

10.

Squarepoint Ops LLC

(0.0988%)

since

2025/06/30

11.

Spartan Total Market Index Pool G

(0.0533%)

since

2025/07/31

12.

Tower Research Capital LLC

(0.021%)

since

2025/06/30

13.

Citigroup Inc

(0.0101%)

since

2025/06/30

14.

Bank of America Corp

(0.0009%)

since

2025/06/30

15.

Advisor Group Holdings, Inc.

(0%)

since

2025/06/30

16.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

17.

Corsair Capital Management LLC

(0%)

since

2025/06/30

18.

Barclays PLC

(0%)

since

2025/06/30

19.

Stonepine Capital Management Llc

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.19

EPS Estimate

-0.21

EPS Difference

0.02

Surprise Percent

9.5238%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2.5)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.